Accustem Sciences Inc. (ACUT) — SEC Filings
Accustem Sciences Inc. (ACUT) — 12 SEC filings. Latest: 8-K (Nov 26, 2025). Includes 6 10-Q, 3 8-K, 2 10-K.
View Accustem Sciences Inc. on SEC EDGAR
Overview
Accustem Sciences Inc. (ACUT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 26, 2025: AccuStem Sciences Inc. filed an 8-K report on November 26, 2025, to disclose other events. The company, incorporated in Delaware, has its principal executive offices at 5 Penn Plaza, New York, NY. The filing does not contain specific details about the 'other events' but serves as a notification to t
Sentiment Summary
Across 12 filings, the sentiment breakdown is: 2 bearish, 10 neutral. The dominant filing sentiment for Accustem Sciences Inc. is neutral.
Filing Type Overview
Accustem Sciences Inc. (ACUT) has filed 3 8-K, 6 10-Q, 2 10-K, 1 8-K/A with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (12)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 26, 2025 | 8-K | AccuStem Sciences Files 8-K Report | low |
| Nov 12, 2025 | 10-Q | Accustem Sciences' Losses Widen Amid R&D Push, Liquidity Concerns Mount | high |
| Aug 14, 2025 | 10-Q | Accustem Sciences' Losses Mount Amid R&D Push, Seeks New Capital | high |
| May 20, 2025 | 10-Q | Accustem Sciences Files Q1 2025 10-Q | low |
| Apr 3, 2025 | 10-K | Accustem Sciences Files 2024 10-K | low |
| Jan 2, 2025 | 8-K/A | AccuStem Sciences Inc. Amends Accountant Change Filing | low |
| Dec 30, 2024 | 8-K | AccuStem Sciences Changes Auditors to Marcum LLP | medium |
| Nov 18, 2024 | 10-Q | Accustem Sciences Files Q3 2024 10-Q | medium |
| Sep 16, 2024 | 10-Q | Accustem Sciences Files Q2 2024 10-Q | medium |
| May 20, 2024 | 10-Q | Accustem Sciences Files 10-Q for Q1 2024 | low |
| Apr 10, 2024 | 8-K | AccuStem Sciences Changes Auditors to BDO USA | low |
| Mar 22, 2024 | 10-K | Accustem Sciences Inc. Files 2023 Annual Report on Form 10-K |
Risk Profile
Risk Assessment: Of ACUT's 11 recent filings, 2 were flagged as high-risk, 3 as medium-risk, and 6 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$399,897 |
| Cash Position | $14,391 |
Industry Context
Accustem Sciences operates in the genomics-based personalized medicine sector, a rapidly evolving field with high R&D intensity. The competitive landscape is characterized by significant innovation and the need for substantial capital investment to bring products to market. Companies in this space often face long development cycles and regulatory hurdles.
Top Tags
10-Q (4) · pharmaceuticals (4) · quarterly-report (3) · sec-filing (2) · Biotechnology (2) · Oncology (2) · Going Concern (2) · Liquidity Risk (2) · R&D Spending (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $1.24M | Increased from $1.13M in prior year, indicating widening losses. |
| Accumulated Deficit | $9.27M | Significant deficit highlighting historical unprofitability and going concern risk. |
| Working Capital Deficit | $2.91M | Indicates current liabilities exceed current assets, a key liquidity concern. |
| Advances Paid | $1.50M | Consideration issued in shares for an intangible asset, a significant non-cash transaction. |
| Advances from Related Party | $957K | Primary source of cash inflow, highlighting reliance on related party support. |
| Cash Balance | $14.39K | Extremely low cash balance for a company with ongoing R&D and operational expenses. |
| Common Shares Outstanding | 16,072,267 | Increased from 12,100,535 at Dec 31, 2024, indicating dilution from stock issuance. |
| R&D Expenses (Q3) | $72.72K | Increased from $31.41K in prior year, showing increased investment in development. |
| Net Loss | $841,811 | Increased from $804,827 in prior year for six months ended June 30, 2025. |
| Research and Development Expenses | $88,550 | Increased from $64,943 in prior year for six months ended June 30, 2025. |
| Fiscal Year End | 2024-12-31 | Reporting period for the 10-K |
| Filing Date | 2025-04-03 | Date the 10-K was submitted to the SEC |
| Reporting Period End Date | 2024-09-30 | Covers the third quarter and nine months of fiscal year 2024. |
| Period End Date | 2024-06-30 | The end of the fiscal quarter for which the report is filed. |
| Previous Fiscal Year End | 2023-12-31 | Provides a comparison point for financial performance and position. |
Frequently Asked Questions
What are the latest SEC filings for Accustem Sciences Inc. (ACUT)?
Accustem Sciences Inc. has 12 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ACUT filings?
Across 12 filings, the sentiment breakdown is: 2 bearish, 10 neutral. The dominant sentiment is neutral.
Where can I find Accustem Sciences Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Accustem Sciences Inc. (ACUT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Accustem Sciences Inc.?
Key financial highlights from Accustem Sciences Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ACUT?
The investment thesis for ACUT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Accustem Sciences Inc.?
Executive information for Accustem Sciences Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Accustem Sciences Inc. stock?
Of ACUT's 11 assessed filings, 2 were flagged high-risk, 3 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Accustem Sciences Inc.?
Forward guidance and predictions for Accustem Sciences Inc. are extracted from SEC filings as they are enriched.